Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Jurgen Harting

Manfred Baumgarth

Dieter Orth

Klaus-Otto Minck

Rolf Gericke

Rochus Jonas

Hanns Wurziger

Ingeborg Lues

Rolf Bergmann

Hans-Jochen Schliep

Josef Kramer

Andreas Fuchs

Hans J Enenkel

Michael Kloft

Hans Schaefer

Hans Radunz

Achim Zesch

The invention relates to novel chroman derivatives of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 have the meanings given in [Patent claim 1], and which, like their salts, show effects on the cardiovascular system and can be used for the treatment or prophylaxis of cardiac insufficiency, angina pectoris, high blood pressure, incontinence and alopecia.

Pyridaziny or oxodihydropyridazinyl chroman derivatives

2-Aryltetraazaindenes of the formula ##STR1## wherein --A-- is --N.dbd.CH--CH.dbd.N-- or --CH.dbd.N--N.dbd.CH--, Ar is unsubstituted phenyl or phenyl mono-, di- or trisubstituted by hydroxyl, mercapto, dialkylamino, trifluoromethyl and/or --Z--R groups, Z is --O--, --S-- or --SO-- and R is alkyl, alkenyl, alkynyl or cyanomethyl, the alkyl, alkenyl and alkynyl groups each having up to 5 C atoms, and their physiologially acceptable salts, exhibit blood pressure, myocardial contraction, and anti-ulcer activities.

Pharmaceutical compositions containing 2-aryltetraazaindenes for

1-(p-2-iso-propoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol and its biocompatible salts are very useful in decreasing the intra-ocular pressure, e.g., to treat glaucoma.

1-(p-2-Isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol for

Hydrocortisone esters of the formula ##STR1## wherein R.sup.1 is H, formyl or acetyl and R.sup.2 is H or CH.sub.3 are antiphlogistically active.

Hydrocortisone esters, pharmaceutical formulations containing these and

Hydrocortisone orthoesters of the formula ##STR1## wherein R.sup.1 and R.sup.2 are independently each H or CH.sub.3 and n is 1 or 2 possess antiphlogistic activity.

Hydrocortisone orthoesters, pharmaceutical formulations thereof and

Sulfides of the general formula ##SPC1## Wherein R.sub.1 is H or alkyl, R.sub.2 is =O, (H,OH), or (H,lower-acyloxy), R.sub.3 is H, OH or lower-acyloxy, R.sub.4 is alkyl or alkyl substituted by F, OH, lower-acyloxy, phenyl or p-tolyl, and A is alkylene which can be mono- or polysubstituted by F, and the physiologically acceptable salts thereof, possess, in addition to a blood-pressure-lowering activity, prostaglandin-type and antiprostaglandin-type effects.

13-Sulfa-prostaglandins

Growing community of inventors

Darmstadt, Germany

Jurgen Harting